Author:
Blagosklonny Mikhail V.,Darzynkiewicz Zbigniew
Reference139 articles.
1. Albanell J, Rojo F, Averbuch S, et al., (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol, 20:110–24.
2. Adjei AA & Rowinsky EK. (2003). Novel anticancer agents in clinical development. Cancer Biol Ther, 2:S5–15.
3. Aoki M, Blazek E & Vogt PK. (2001). A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci USA, 98:136–41.
4. Bacus SS, Altomare DA, Lyass, L, et al., (2002). AKT2 is frequently upregulated in HER-2/neu-positive, breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene, 21:3532–40.
5. Baldwin RL, Tran H & Karlan BY. (2003). Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res, 63:1413–19.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献